Kestra Private Wealth Services LLC trimmed its holdings in shares of Humana Inc. (NYSE:HUM – Get Rating) by 17.6% during the first quarter, Holdings Channel.com reports. The fund owned 1,495 shares of the insurance provider’s stock after selling 319 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Humana were worth $651,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Tcwp LLC bought a new position in shares of Humana during the first quarter worth approximately $25,000. Riverview Trust Co acquired a new position in Humana during the first quarter worth about $32,000. Bank of New Hampshire acquired a new stake in Humana in the first quarter valued at approximately $36,000. CNB Bank acquired a new position in Humana in the 1st quarter worth about $44,000. Finally, DeDora Capital Inc. acquired a new stake in Humana during the 1st quarter worth approximately $48,000. Institutional investors and hedge funds own 93.50% of the company’s stock.
Humana Trading Up 0.5 %
Shares of Humana stock opened at $499.79 on Monday. The firm has a market cap of $63.25 billion, a price-to-earnings ratio of 20.40, a PEG ratio of 1.49 and a beta of 0.77. Humana Inc. has a twelve month low of $351.20 and a twelve month high of $504.99. The business has a 50-day moving average price of $486.23 and a 200-day moving average price of $459.41. The company has a quick ratio of 1.53, a current ratio of 1.53 and a debt-to-equity ratio of 0.73.
Humana Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 28th. Stockholders of record on Friday, September 30th will be given a $0.7875 dividend. The ex-dividend date is Thursday, September 29th. This represents a $3.15 annualized dividend and a dividend yield of 0.63%. Humana’s payout ratio is presently 12.86%.
Wall Street Analyst Weigh In
HUM has been the topic of a number of recent analyst reports. Sanford C. Bernstein assumed coverage on Humana in a research note on Thursday, May 26th. They issued a “market perform” rating and a $506.00 price objective on the stock. Oppenheimer increased their target price on shares of Humana from $520.00 to $550.00 and gave the company an “outperform” rating in a report on Friday. SVB Leerink boosted their target price on Humana from $535.00 to $540.00 and gave the stock an “outperform” rating in a research note on Thursday, July 28th. Truist Financial boosted their target price on shares of Humana from $550.00 to $570.00 and gave the company a “hold” rating in a research note on Friday. Finally, Credit Suisse Group set a $548.00 price objective on shares of Humana in a report on Tuesday, July 19th. Five research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, Humana presently has a consensus rating of “Moderate Buy” and an average price target of $515.17.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
- Get a free copy of the StockNews.com research report on Humana (HUM)
- Kroger’s is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.